Aerolla schreef: ↑Gisteren 07:34 Jij gaat er altijd van uit dat een daling automatisch leidt tot een koopkans..
UHC is gedaald met een zeer goede reden, ze hebben niet bepaald een president die meewerkt, en daarnaast nog vele andere problemen...

UnitedHealth Group (UHG) and other large healthcare companies are often described as "middlemen" in the healthcare industry due to their roles in managing prescription drug benefits and other healthcare services. These companies, particularly their pharmacy benefit manager (PBM) subsidiaries like OptumRx, face scrutiny for potentially inflating drug costs and limiting patient access to medications.
Here's a breakdown of the situation:

What are these "middlemen"?
Pharmacy Benefit Managers (PBMs):
Companies like OptumRx (owned by UnitedHealth), CVS Caremark, and Express Scripts (owned by Cigna) manage prescription drug benefits for health insurance plans, employers, and government programs.

Their role:
PBMs negotiate drug prices with pharmaceutical manufacturers, determine which drugs are covered by insurance plans (formularies), and manage prescription claims.
Concerns about their role:

Inflated drug costs:
PBMs negotiate rebates and discounts with drug manufacturers, but these savings are not always passed on to patients, and in some cases, PBMs may even benefit from higher drug prices.

Lack of transparency:
The intricate and opaque nature of PBM operations makes it difficult to understand how they determine drug prices and manage costs.

Steering patients:
PBMs may steer patients towards pharmacies they own or have financial relationships with, potentially limiting patient choice and access.

Conflicts of interest:
PBMs are often owned by large health insurance companies, creating potential conflicts of interest where they may prioritize their own financial interests over patient needs.

Antitrust concerns:
The concentration of market power in the hands of a few large PBMs raises antitrust concerns, as it can stifle competition and limit access to affordable medications.
Recent developments:

FTC investigation:
The Federal Trade Commission (FTC) is investigating the practices of major PBMs, including UnitedHealth's OptumRx, CVS Caremark, and Express Scripts.

Lawsuits:
The FTC is reportedly planning to sue UnitedHealth, Cigna, and CVS over their practices as drug middlemen.
Market consolidation:
The FTC has highlighted how market consolidation among PBMs has led to increased costs and limited access to medications.

Public scrutiny:
There is growing public awareness and frustration with the role of these "middlemen" in healthcare, particularly concerning prescription drug costs and access.
UnitedHealth's response:
UnitedHealth has stated that it is working to eliminate prior authorization requirements and has denied allegations of wrongdoing.
In essence, the term "middlemen" in the context of UnitedHealth and the healthcare industry refers to the companies that manage prescription drug benefits and other healthcare services, and the concerns revolve around their potential to inflate costs, limit access, and create conflicts of interest.

Umi schreef: ↑Gisteren 13:27 Waar ik mij zorgen over maak bij deze... Al weet ik niet welk % van de winst hieruit komt bij UH.

karine schreef: ↑Gisteren 16:15 Zie jij een bedrijf als UNH met 400.000 werknemers failliet gaan?

karine schreef: ↑27 juni 2025, 21:42 UnitedHealth Group heel zwaar afgestraft(YTD -40%), zou het niet stilaan de moment zijn om positie in te nemen?
Trends schrijft ook : Beleggingstip van de week: UnitedHealth Group